VariSeed 7.0 Treatment Planning Tool for Permanent Seed Implant Brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 5
Volume 11
Issue 5

PALO ALTO, California-Varian Medical Systems has released VariSeed 7.0, the company’s newest treatment planning software for permanent seed implant brachytherapy used in treating prostate cancer. VariSeed 7.0 gives physicians the ability to use real-time images generated during the implant procedure to deliver precise accurate doses, the company said in a news release.

PALO ALTO, California—Varian Medical Systems has released VariSeed 7.0, the company’s newest treatment planning software for permanent seed implant brachytherapy used in treating prostate cancer. VariSeed 7.0 gives physicians the ability to use real-time images generated during the implant procedure to deliver precise accurate doses, the company said in a news release.

Using VariSeed 7.0, radiation oncologists can generate a treatment plan, use it to implant the seeds, and see how the radiation dose will develop within the patient’s anatomy while the patient is still in the operating room. This allows for fine-tuning and more precise adjustments on the spot, the company said.

VariSeed 7.0 also introduces the ability to superimpose different kinds of diagnostic images such as MRI and single photon emission computed tomography (SPECT), which show the extent of disease, with CT and ultrasound images, which show anatomy and positioning. This enables physicians to adjust implants according to an individual patient’s disease characteristics.

VariSeed 7.0 is now available to new customers and as a software upgrade to clinics that already use VariSeed for planning and documenting prostate seed implant dosimetry.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
4 experts in this video
Related Content